Aquestive Therapeutics (AQST) Competitors $2.27 -0.12 (-5.02%) Closing price 04:00 PM EasternExtended Trading$2.30 +0.03 (+1.15%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AQST vs. ARDX, COLL, NTLA, RCUS, AVDL, SYRE, PHVS, CVAC, CRMD, and NAGEShould you be buying Aquestive Therapeutics stock or one of its competitors? The main competitors of Aquestive Therapeutics include Ardelyx (ARDX), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), Arcus Biosciences (RCUS), Avadel Pharmaceuticals (AVDL), Spyre Therapeutics (SYRE), Pharvaris (PHVS), CureVac (CVAC), CorMedix (CRMD), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry. Aquestive Therapeutics vs. Ardelyx Collegium Pharmaceutical Intellia Therapeutics Arcus Biosciences Avadel Pharmaceuticals Spyre Therapeutics Pharvaris CureVac CorMedix Niagen Bioscience Ardelyx (NASDAQ:ARDX) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership. Do analysts recommend ARDX or AQST? Ardelyx currently has a consensus target price of $10.39, indicating a potential upside of 160.37%. Aquestive Therapeutics has a consensus target price of $10.67, indicating a potential upside of 369.90%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aquestive Therapeutics is more favorable than Ardelyx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ardelyx 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90Aquestive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer ARDX or AQST? Ardelyx received 322 more outperform votes than Aquestive Therapeutics when rated by MarketBeat users. However, 68.45% of users gave Aquestive Therapeutics an outperform vote while only 67.46% of users gave Ardelyx an outperform vote. CompanyUnderperformOutperformArdelyxOutperform Votes53967.46% Underperform Votes26032.54% Aquestive TherapeuticsOutperform Votes21768.45% Underperform Votes10031.55% Which has better earnings and valuation, ARDX or AQST? Aquestive Therapeutics has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArdelyx$361.71M2.64-$39.14M-$0.22-18.14Aquestive Therapeutics$54.23M4.16-$7.87M-$0.59-3.85 Do institutionals and insiders believe in ARDX or AQST? 58.9% of Ardelyx shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 4.8% of Ardelyx shares are held by insiders. Comparatively, 8.4% of Aquestive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to ARDX or AQST? In the previous week, Aquestive Therapeutics had 6 more articles in the media than Ardelyx. MarketBeat recorded 18 mentions for Aquestive Therapeutics and 12 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.85 beat Aquestive Therapeutics' score of 0.26 indicating that Ardelyx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Aquestive Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is ARDX or AQST more profitable? Ardelyx has a net margin of -11.73% compared to Aquestive Therapeutics' net margin of -59.75%. Aquestive Therapeutics' return on equity of 0.00% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets Ardelyx-11.73% -24.87% -10.51% Aquestive Therapeutics -59.75%N/A -33.96% Which has more risk & volatility, ARDX or AQST? Ardelyx has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Aquestive Therapeutics has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500. SummaryAquestive Therapeutics beats Ardelyx on 10 of the 19 factors compared between the two stocks. Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AQST vs. The Competition Export to ExcelMetricAquestive TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$225.48M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-5.048.9226.8419.71Price / Sales4.16250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book-1.436.466.794.50Net Income-$7.87M$143.98M$3.23B$248.18M7 Day Performance2.25%3.04%4.07%1.14%1 Month Performance-12.02%7.44%12.52%15.20%1 Year Performance-28.62%-2.46%16.83%6.56% Aquestive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AQSTAquestive Therapeutics1.3111 of 5 stars$2.27-5.0%$10.67+369.9%-25.1%$225.48M$54.23M-5.04160News CoverageAnalyst RevisionARDXArdelyx4.4986 of 5 stars$4.06+4.6%$10.39+155.9%-47.3%$971.38M$361.71M-25.3890Insider TradeCOLLCollegium Pharmaceutical4.0712 of 5 stars$29.83-1.3%$43.80+46.8%-12.3%$958.50M$664.28M12.86210News CoveragePositive NewsNTLAIntellia Therapeutics4.6481 of 5 stars$9.06+6.6%$36.90+307.3%-62.6%$938.46M$45.57M-1.67600Analyst ForecastHigh Trading VolumeRCUSArcus Biosciences3.5699 of 5 stars$8.70+1.6%$25.67+195.0%-47.4%$921.20M$141M-2.76500Positive NewsAVDLAvadel Pharmaceuticals2.2178 of 5 stars$9.35+3.8%$19.43+107.8%-40.3%$903.48M$194.45M-11.8470SYRESpyre Therapeutics2.3372 of 5 stars$14.88-2.0%$53.40+258.9%-58.2%$896.91M$890,000.00-1.99100Positive NewsGap DownPHVSPharvaris1.2909 of 5 stars$16.69+0.8%$40.67+143.7%-16.5%$872.72MN/A-5.9630CVACCureVac3.7226 of 5 stars$3.87+4.0%$14.00+261.8%+25.9%$868.19M$535.18M7.04880News CoverageUpcoming EarningsGap DownCRMDCorMedix2.113 of 5 stars$12.75+3.8%$15.00+17.6%+153.9%$864.77M$82.55M-15.7430NAGENiagen BioscienceN/A$10.93-0.2%N/AN/A$860.96M$107.93M64.29120 Related Companies and Tools Related Companies ARDX Alternatives COLL Alternatives NTLA Alternatives RCUS Alternatives AVDL Alternatives SYRE Alternatives PHVS Alternatives CVAC Alternatives CRMD Alternatives NAGE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AQST) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AQST Stock Free AQST Stock Alerts